Sunday, 18 February 2018

The U.S. Food and Drug Administration granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients

The U.S. Food and Drug Administration said late on Friday it granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.
The green light - which had been expected following positive clinical data last year - gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.
Analysts believe using Imfinzi in so-called stage III lung cancer, where cancer has only spread locally, opens up an annual sales opportunity worth around $2 billion. Importantly, AstraZeneca has a lead of two to three years over other drug companies in this particular area.

No comments:

Post a Comment

Mental health could cost the global economy up to $16 trillion between 2010 and 2030

According to an expert, mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 tr...